News | PET-CT | November 18, 2015

Mirada Medical Providing Imaging Software for Cancer Diagnostics Across England

Company will deploy XD3 Advanced image review and analysis software at 30 National Health Service PET/CT departments

Mirada Medical, Alliance Medical, NHS, National Health Service, United Kingdom, PET/CT, cancer diagnostics

November 18, 2015 — Mirada Medical Ltd has announced that its XD3 Advanced image review and analysis software is being deployed by Alliance Medical in partnership with 30 National Health Service (NHS) hospital positron emission tomography/computed tomography (PET/CT) departments nationwide.

In January 2015 the NHS selected a collaborative network, led by Alliance Medical, to provide PET/CT scanning services across the country, following a competitive tender process.

The network also involves a number of leading academic institutions, including The Christie NHS Foundation Trust and Leeds Teaching Hospitals NHS Trust, as well as local NHS and charitable partners. 

PET/CT imaging is critical for accurate diagnosis, staging and follow-up of many cancers. It enables treating clinicians to see precisely where the tumors are located and how they change or spread over the course of the disease and its treatment. More than 50,000 PET/CT scans are read in England each year. Mirada's XD3 software provides powerful tools to combine quantification information from these scans, enabling clinicians to confidently assess their patients.

As part of the contract Oxford-based Mirada Medical are delivering their diagnostic imaging software, XD3 Advanced, to the whole collaborative network.

“Mirada’s XD3 software provides a robust reporting solution with state-of-the-art features facilitating quantitative data analysis. It is a reliable and efficient platform for PET/CT reporting that gives confidence in image interpretation. This is key to the assessment and treatment efficacy and effective ongoing cancer care,” said Andrew Scarsbrook, M.D., consultant radiologist and nuclear medicine physician, Leeds Teaching Hospitals NHS Trust.

“Alliance Medical believes that our PET/CT collaborative network, together with Mirada Medical software, will result in the highest quality clinical analysis combined with improvements in productivity and associated cost,” said Johann Alberts, M.D., director of PET/CT operations, Alliance Medical.

Mirada's software products are available to the NHS and to thousands of users throughout the world under its own brand, and on an OEM basis through select global leading healthcare companies.

For more information:

Related Content

Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Intronix Technologies Developing Augmented Reality Medical Simulation for Neuromuscular Injection Procedures
News | Advanced Visualization | September 11, 2017
Canadian-based Intronix Technologies will be working with Roy Eagleson, Ph.D., professor in the Department of...
Median Technologies to Lead Roundtable on Applications of iBiopsy for Nonalcoholic Steatohepatitis
News | Advanced Visualization | September 07, 2017
September 7, 2017 — Median Technologies announced that it will lead a scientific and medical roundtable on Sept.
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Carestream dose management
Sponsored Content | Whitepapers | Advanced Visualization | August 17, 2017
It's critical for today's healthcare professionals to understand the balance between the risks and benefits of any X-...
Carestream Launches MR Brain Perfusion and Diffusion Modules for Vue PACS
Technology | Advanced Visualization | August 16, 2017
Carestream Health recently introduced new MR (magnetic resonance) Brain Perfusion and MR Brain Diffusion modules that...
Overlay Init